Abstract
In this study, the environmental impacts of three ibuprofen production routes, namely, the BHC, the Bogdan, and the newly developed enzymatic synthetic routes (modified Bogdan process), are assessed and compared by the application of life cycle assessment (LCA). Based on the data obtained through literature and laboratory-based experiments, a pilot-scale production with a capacity of 500 g/day of ibuprofen was simulated to generate inventory data for the LCA study, using Aspen Plus V11. The well-established BHC process was chosen as the benchmark to quantify the operational and environmental benefits of the innovative enzymatic Bogdan flow synthetic process. The comparison highlights the benefit of adopting the modified Bogdan synthesis route via an enzymatic catalyst. Results show that a general reduction of environmental impact is achievable across the whole set of impact categories of the analysis, and the magnitude of such reduction depends on the efficiency of recycling in the production system. Considering a 50% efficiency of recycling, the modified Bogdan system achieves lower environmental impacts in some impact categories like Acidification, Ecotoxicity of freshwater, Human toxicity, Particulate matter, and Resource depletion (mineral, fossils, renewables) while having higher impacts on the rest of the impact categories. Yet, the new process proposed here scores better environmental performances in all of the impact categories when the enzyme recycling is close to 100%, which is promising for future technology development.
Original language | English |
---|---|
Pages (from-to) | 13135-13150 |
Number of pages | 16 |
Journal | ACS Sustainable Chemistry and Engineering |
Volume | 9 |
Issue number | 39 |
DOIs | |
Publication status | Published - 4 Oct 2021 |
Bibliographical note
Funding Information:This work was supported by the EU-FET Open project ONE-FLOW “Catalyst Cascade Reactions in ‘One-Flow’ within a Compartmentalized, Green-Solvent ‘Digital Synthesis Machinery’—End-to-End Green Process Design for Pharmaceuticals” (EU Proposal Number 737266) and the start-up grant for Prof. Hessel provided by the University of Adelaide. The authors would like to sincerely thank our partners at TU Delft, Prof. Dr. Ulf Hanefeld and Dr. Fabio Tonin, for providing the Mycobacterium smegmatis enzyme. Our sincere thanks to Prof. Hans-Jürgen Federsel at the Department of Chemical Process and Pharmaceutical Development, RISE Research Institutes of Sweden, and EnginZyme (Sweden) for the donation of Amano lipase enzyme.
Funding
This work was supported by the EU-FET Open project ONE-FLOW “Catalyst Cascade Reactions in ‘One-Flow’ within a Compartmentalized, Green-Solvent ‘Digital Synthesis Machinery’—End-to-End Green Process Design for Pharmaceuticals” (EU Proposal Number 737266) and the start-up grant for Prof. Hessel provided by the University of Adelaide. The authors would like to sincerely thank our partners at TU Delft, Prof. Dr. Ulf Hanefeld and Dr. Fabio Tonin, for providing the Mycobacterium smegmatis enzyme. Our sincere thanks to Prof. Hans-Jürgen Federsel at the Department of Chemical Process and Pharmaceutical Development, RISE Research Institutes of Sweden, and EnginZyme (Sweden) for the donation of Amano lipase enzyme.
Keywords
- aspen simulation
- Bogdan flow process
- enzyme
- ibuprofen
- life cycle assessment